Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novo Nordisk to apply Zosano's delivery system to Type II diabetes candidate; deal terminated

Executive Summary

Zosano Pharma Inc. (transdermal drug delivery) granted Novo Nordisk AS exclusive worldwide rights to use its microneedle patch system in the development and commercialization of glucagon-like peptide-1 (GLP-1) analogues.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Transdermal
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register